

SHINING A LIGHT ON HIGH-PRICED DRUGS



The Los Angeles Times and Sacramento Bee joined other newspapers, leaders and organizations throughout the state in support of SB 17 (Hernandez), which would bring Pharma's drug pricing tactics out of the dark. The widely supported bill is headed for the Assembly Appropriations Committee next month.

[Pharma ducks Obamacare debate and fights transparency. And yet it wants our trust](#) Sacramento Bee Editorial Board | July 24, 2017

THE SACRAMENTO BEE 

"Back in Sacramento, drug companies fight to kill Senate Bill 17, which would force some transparency in drug pricing... It would apply to drugs that cost more than \$40 a month and would require drug companies to issue 60-day notices when they intend to raise prices by more than 10 percent over a two-year period. **It seems perfectly reasonable, so much so that Sen. John McCain, R-Ariz., working with congressional Democrats, has introduced similar legislation.**"

[Editorial: Shining a light on prescription drug pricing](#) Los Angeles Times Editorial Board | July 24, 2017

Los Angeles Times

"The drug companies' biggest fear seems to be that the measure is a stalking horse for price caps, which they say would dry up the investment they rely on to fund R&D. But **that's a wholly separate debate, and one that should be informed by the kind of industry data that SB 17 aims to collect.**"

How SB 17 Will Address The Growing Affordability Crisis



Drug companies will be required to give notice of major price increases for the most expensive drugs, allowing payers to plan ahead.



Lawmakers can review historical trends on drug costs to inform solutions and ultimately craft appropriate legislation.



The public will have access to basic information on what drives price hikes and drug spending, just as they do in most other consumer-oriented industries.